Outlook Therapeutics, Inc. (OTLK) saw its stock rally 12% overnight heading into Monday after the FDA approved Lytenava on Friday, the company's eye drug for treating wet age-related macular degeneration (wet AMD). The approval came ahead of the FDA's July 29 target date and followed a May ruling by the FDA's Office of New Drugs that allowed Outlook to resubmit its application in June after a December 2025 rejection. Lytenava is the first and only FDA-approved bevacizumab formulation developed specifically for use in the eye, entering a U.S. market for anti-VEGF retinal treatments estimated at approximately $8.5 billion annually.
OTLK stock jumped 6% on Friday to $1.41, snapping two straight sessions of losses.
FDA Approves Lytenava for Wet AMD Ahead of Target Date
Outlook Therapeutics announced on Friday that the FDA approved Lytenava for wet AMD, making it the first and only FDA-approved version of bevacizumab developed specifically for use in the eye. The decision came ahead of the FDA's July 29 target date and marks a turnaround after several regulatory setbacks.
In December 2025, the FDA rejected Outlook's application and requested additional evidence of the drug's effectiveness. Outlook appealed, and in May the FDA's Office of New Drugs ruled that the existing data were sufficient and that no additional clinical trials were needed. That decision allowed Outlook to resubmit its application in June, leading to Friday's approval.
Outlook Therapeutics Prepares U.S. Launch Before Year-End
Outlook estimates the U.S. market for anti-VEGF retinal treatments at about $8.5 billion annually, with millions of eye injections administered each year. Bevacizumab has been used for more than 20 years in retinal care, including for wet AMD, but largely on an off-label basis. Lytenava was developed specifically for injection into the eye and is now FDA-approved for wet AMD.
Outlook stated that Lytenava will receive 12 years of U.S. market exclusivity under biologics law. The drug is already approved in the European Union and U.K., with commercial launches underway in Germany, Austria and the U.K.
Outlook expects Lytenava to become available to eligible U.S. patients before year-end. The company is expanding reimbursement and patient-support access, building a specialized retina commercial organization and supporting physicians as it prepares for rollout.
Analysts Set Average Price Target at $5.50 with 290% Upside
Koyfin estimates show a 12-month average price target of $5.50 for Outlook Therapeutics, with targets ranging from $0.50 to $10. The average target implies a 290% upside from current levels, while the $10 high target would imply a 609% upside. The $0.50 low target would represent a 65% downside.
Koyfin lists four covering analysts, with two rating OTLK a 'Buy' and two assigning a 'Hold'. There are no 'Sell' or 'Strong Sell' ratings and no analysts currently at 'Strong Buy'.
Retail Sentiment Turns Extremely Bullish on Stocktwits
On Stocktwits, retail sentiment for OTLK jumped to 'extremely bullish' from 'bullish' levels amid a 20% rise in 24-hour message volumes.
One user said, "The next chapter is all about successful commercialization and market adoption. Let's go!"
Another user said, "The biggest risk, the FDA rejection, is now behind us. The focus shifts entirely to execution: how quickly they can launch LYTENAVA in the US, how many doctors and patients adopt it, and how strong the initial uptake will be."
OTLK stock has declined 30% over the past year.
FAQ
What did the FDA approve for Outlook Therapeutics on Friday?
The FDA approved Lytenava, Outlook Therapeutics' eye drug for treating wet age-related macular degeneration (wet AMD), on Friday. The approval came ahead of the FDA's July 29 target date.
Why did OTLK stock rally 12% overnight?
OTLK stock rallied 12% overnight heading into Monday following the FDA's approval of Lytenava on Friday. The approval removed a major regulatory hurdle after the FDA had rejected the application in December 2025 and Outlook won an appeal in May.
What is the analyst price target for OTLK stock?
Analysts set a 12-month average price target of $5.50 for OTLK stock, with targets ranging from $0.50 to $10. The average target implies a 290% upside from current levels.
